Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
15.07
-0.26 (-1.70%)
At close: Jun 27, 2025, 4:00 PM
15.02
-0.05 (-0.33%)
After-hours: Jun 27, 2025, 7:54 PM EDT
Dr. Reddy's Laboratories Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Dr. Reddy's Laboratories stock ranges from a low of $16.9 to a high of $17. The average analyst price target of $16.95 forecasts a 12.48% increase in the stock price over the next year.
Price Target: $16.95 (+12.48%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Dr. Reddy's Laboratories stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 1 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HSBC | HSBC | Hold → Strong Buy Upgrades $14 → $17 | Hold → Strong Buy | Upgrades | $14 → $17 | +12.14% | Jun 5, 2025 |
Barclays | Barclays | Buy Maintains $17 → $17 | Buy | Maintains | $17 → $17 | +12.81% | Nov 6, 2024 |
Barclays | Barclays | Buy Maintains $16 → $17 | Buy | Maintains | $16 → $17 | +15.46% | Jul 30, 2024 |
Barclays | Barclays | Buy Maintains $16 → $16 | Buy | Maintains | $16 → $16 | +7.50% | May 8, 2024 |
Barclays | Barclays | Buy Maintains $15 → $16 | Buy | Maintains | $15 → $16 | +6.17% | Jan 29, 2024 |
Financial Forecast
Revenue This Year
358.87B
from 325.54B
Increased by 10.24%
Revenue Next Year
355.33B
from 358.87B
Decreased by -0.99%
EPS This Year
72.80
from 67.78
Increased by 7.41%
EPS Next Year
58.36
from 72.80
Decreased by -19.83%
Financial currency is INR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2026 | 2027 | 2029 |
---|---|---|---|
High | 391.8B | 394.9B | 419.5B |
Avg | 358.9B | 355.3B | 407.5B |
Low | 309.2B | 318.7B | 391.6B |
Revenue Growth
Revenue Growth | 2026 | 2027 | 2029 |
---|---|---|---|
High | 20.3% | 10.0% | 18.1% |
Avg | 10.2% | -1.0% | 14.7% |
Low | -5.0% | -11.2% | 10.2% |
EPS Forecast
EPS | 2026 | 2027 |
---|---|---|
High | 93.45 | 86.28 |
Avg | 72.80 | 58.36 |
Low | 58.02 | 34.59 |
EPS Growth
EPS Growth | 2026 | 2027 |
---|---|---|
High | 37.9% | 18.5% |
Avg | 7.4% | -19.8% |
Low | -14.4% | -52.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.